Inhibitors of Akt activity

1. The TFA salt of a compound which is selected from:

1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

N,N-dimethyl-1-[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methanamine;

1-{1-[4-(3-phenylbenzo[g]quinoxalin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

or a stereoisomer thereof.

2. A compound which is selected from:

1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

N,N-dimethyl-1-[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methanamine;

1-{1-[4-(3-phenylbenzo[g]quinoxalin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one;

or a pharmaceutically acceptable salt or a stereoisomer thereof.

3. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of claim 2 .

4. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 2 .

5. A compound of the Formula A:

wherein:

n is 0, 1 or 2;

p is 0, 1, 2 or 3;

is selected from:

R 1 is independently selected from:

1) OH,

2) OC 1 -C 6 alkyl, and

3) C 1 -C 6 alkyl;

R 2 is independently selected from:

1) C 1 -C 6 alkyl,

2) OH,

3) OC 1 -C 6 alkyl,

4) CF 3 ,

5) CN, and

6) halogen;

R 3 and R 4 are: H;

R 5 and R 6 are independently selected from: H and C 1 -C 6 alkyl; or

R 5 and R 6 can be taken together with the nitrogen to which they are attached to form:

optionally substituted with Q;

Q is selected from:

or a pharmaceutically acceptable salt or a stereoisomer thereof.